China’s decision to abandon its zero-COVID policy to supress the spread of the SARS-CoV-2 virus helped drive up Haleon’s sales in the first half of 2023. And the company sees runway for continued growth in its second-largest market by sales.
China Helps Propel Haleon To Double-Digit Sales Gain In First Half
China sales that jumped by 23% helped Haleon post first-half group turnover up by 10.6%. The company sees lots of headroom for further growth in the country given the relatively low per capita spend on OTC and VMS compared to the US and Europe.
More from China
• By
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.
• By
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
• By
Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.
More from Asia
• By
Self-care industry representatives from GSCF/AESGP, Bayer and Opella stress the seriousness of the global climate crisis at the 2024 GSCF, APSMI, TSMIA Joint Congress in Bangkok, Thailand, and also share iniatives that are attempting to deal with this crisis, for example replacing PVC in medicine blister packs with more easily recyclable materials.
• By
GSCF research shows that self-care already saves the Asia Pacific region more than $30bn a year in healthcare system costs. To realize higher gains, health literacy, Rx-to-OTC switch and digitalization need to be leveraged, according to the EU-ASEAN Business Council.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.